Manidipine plus delapril in patients with Type 2 diabetes and hypertension: Reducing cardiovascular risk and end-organ damage

Expert Review of Cardiovascular Therapy

Volumn 5, Issue 2, 2007, Pages 147-159

  Coca, Antonio ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Cardiovascular protection; Delapril; Diabetes; Hypertension; Manidipine; Manidipine plus delapril; Nephroprotection

Indexed keywords

AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BENAZEPRIL; CALCIUM ANTAGONIST; CAPTOPRIL; DELAPRIL; DELAPRIL PLUS MANIDIPINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENALAPRIL PLUS HYDROCHLOROTHIAZIDE; FELODIPINE; HYDROCHLOROTHIAZIDE PLUS IRBESARTAN; HYDROCHLOROTHIAZIDE PLUS LISINOPRIL; HYDROCHLOROTHIAZIDE PLUS OLMESARTAN; HYDROCHLOROTHIAZIDE PLUS RAMIPRIL; HYDROCHLOROTHIAZIDE PLUS VALSARTAN; IRBESARTAN; ISRADIPINE; LACIDIPINE; LERCANIDIPINE; LISINOPRIL; MANIDIPINE; NICARDIPINE; NIFEDIPINE; PLACEBO; RAMIPRIL; THIAZIDE DIURETIC AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALSARTAN;

ANKLE EDEMA; ANXIETY DISORDER; ARTICLE; BLOOD PRESSURE REGULATION; BRONCHITIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; COUGHING; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DIZZINESS; DRUG ABSORPTION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ESSENTIAL HYPERTENSION; FATIGUE; FIBRINOLYSIS; HEART PALPITATION; HIGH RISK POPULATION; HUMAN; HYPERTENSION; INSULIN RESISTANCE; LEG EDEMA; META ANALYSIS; MONOTHERAPY; MORBIDITY; MORTALITY; NAUSEA AND VOMITING; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORTHOSTATIC HYPOTENSION; PHARMACODYNAMICS; PRACTICE GUIDELINE; RENAL PROTECTION; RISK REDUCTION; SIDE EFFECT; SYSTEMATIC REVIEW; THROMBOSIS; VERTIGO;

BLOOD PRESSURE DETERMINATION; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DIHYDROPYRIDINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERTENSION; INDANS; MALE; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS;

EID: 33947611971     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.5.2.147     Document Type: Article

References (62)

1. Powers AC. Diabetes Mellitus. In: Harrison's Principles of Internal Medicine (16th Edition). Kasper DL, Fauci AS, Longa DL, Braunwald E, Hauser SL, Jameson JL (Eds). McGraw-Hill, OH, USA, 2152-2180 (2005).
2. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 16, 434-444 (1993).
3. Chobanian AV, Bakris GL, Black HR et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. JAMA 289, 2560-2572 (2003).
4. Geiss LS, Rolka DB, Engelgau MM. Elevated blood pressure among U.S. adults with diabetes, 1988-1994. Am. J. Prev. Med. 22, 42-48 (2002).
5. Teuscher A, Egger M, Hermann JB. Diabetes and hypertension. Blood pressure in clinical diabetic patients and a control population. Arch. Intern. Med. 149, 1942-1945 (1989).
6. Curb JD, Pressel SL, Cutler JA et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. JAMA 276, 1886-1892 (1996).
7. European Society of Hypertension-European Society of Cardiology Guidelines Committee.2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J. Hypertens. 21, 1011-1053 (2003).
8. Guidelines Sub-Committee. 1999 World Health Organization International Society of Hypertension guidelines for the management of hypertension. J. Hypertens. 17, 151-183 (1999).
9. Gradman AH, Acevedo C. Evolving strategies for the use of combination therapy in hypertension. Curr. Hypertens. Reports 4, 343-349 (2002).
10. Dahlof B, Sever, PS, Poulter, NR et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 366, 895-906 (2005).
11. Richard S. Vascular effects of calcium channel antagonists: new evidence. Drugs 65(Suppl. 2), 1-10 (2005).
12. McKeage K, Scott LJ. Manidipine: a review of its use in the management of hypertension. Drugs 64, 1923-1940 (2004).
13. Murakami K, Kimura G, Imanishi M et al. Effect of manidipine, a new calcium antagonist, on intrarenal hemodynamics in essential hypertension. Blood Press. 1(Suppl. 3), 114-118 (1992).
14. Hayashi K, Ozawa Y, Fujiwara K et al. Role of actions of calcium antagonists on efferent arterioles - with special references to glomerular hypertension. Am. Nephrol. 23, 229-244 (2003).
15. Takabatake T, Ohta H, Sasaki T et al. Renal effects of manidipine hydrochloride. A new calcium antagonist in hypertensive patients. Eur. J. Clin. Pharmacol. 45, 321-325 (1993).
16. Martinez-Martin F, Rodriguez-Rosas H, Peiro-Martinez I et al. Relationship between sympathetic activation, pulse pressure and heart rate in hypertensive Type 2 diabetic patients with microalbuminuria, treated with manidipine vs amlodipine [abstract]. J. Hypertens. 23(Suppl. 2), S376 (2005).
17. Fogari R, Zoppi A, Corradi L et al. Effects of different dihydropyridine calcium antagonists on plasma norepinephrine in essential hypertension. J. Hypertens. 18, 1871-1875 (2000).
18. Razzetti R, Acerbi D. Pharmacokinetic and pharmacologic properties of delapril, a lipophilic nonsulfhydryl angiotensin-converting enzyme inhibitor. Am. J. Cardiol. 75, 7F-12F (1995).
19. Saruta T, Nishikawa K. Characteristics of a new angiotensin converting enzyme inhibitor: delapril. Am. J. hypertens. 4(1 Pt 2), 23S-28S (1991).
20. Rizzoni D, Bevilacqua M, Gobbato C et al. Blood pressure lowering effects of delapril and manidipine in hypertensive patients with Type 2 diabetes not adequately controlled by monotherapy. High. Blood. Press. Cardiovasc. Prev. 12, 180 (2005).
21. Mugellini A, Preti P, Zoppi A et al. Effect of delapril-manidipine combination vs irbesartan-hydrochlorothiazide combination on fibrinolytic function in hypertensive patients with Type II diabetes mellitus. J. Hum. Hypertens. 18, 687-691 (2004).
22. Mugellini A, Lazzari P, Zoppi A et al. Effect of delapril manidipine combination vs olmesartan hydrochlorothiazide combination on insulin sensitivity in obese hypertensive patients. J. Hypertens. 24(Suppl. 4), S217 (2006).
23. Cheer SM, McClellan K. Manidipine: a review of its use in hypertension. Drugs 61, 1777-1799 (2001).
24. Rossillon D, Stockis A, Poli G et al. Food effect on the oral bioavailability of manidipine: single dose, randomized, crossover study in healthy male subjects. Eur. J. Drug Metab. Pharmacokinet. 23, 197-202 (1998).
25. Morimoto S, Matsumura Y. Manidipine hydrochloride [CV 4093 (2HCL)]. Cardiovasc. Drug Rev 9, 207-222 (1991).
26. Deroubaix X, Lins R, Lens S et al. Single dose pharmacokinetics of manidipine in hepatic impaired patients and healthy controls. Int. J. Clin. Pharmacol. Ther. 36, 386-391 (1998).
27. Onoyama K, Nanishi F, Okuda S et al. Pharmacokinetics of a new angiotensin I converting enzyme inhibitor (delapril) in patients with deteriorated kidney function and in normal control subjects. Clin. Pharmacol. Ther. 43, 242-249 (1988).
28. Stockis A, Gengler C, Goethals F. et al. Single oral dose pharmacokinetic interaction study of manidipine and delapril in healthy volunteers. Arzneimittelforschung 53, 627-634 (2003).
29. Stockis A, De Bruyn S, Gengler C et al. Pharmacokinetics and tolerability of a new manidipine and delapril fixed oral combination in young and elderly subjects. Arzneimittelforschung 53, 554-561 (2003).
30. Bacchelli S, Degli Esposti D, Alberici M et al. Effects of the combination of different doses of manidipine and delapril in hypertensive patients. Am. J. hypertens. 15(4 Pt 2), 45A-46A (2002).
31. Ogihara T, Kaneko Y, Ikeda M et al. Clinical evaluation of delapril in Japan. Report from the Japan Study Group on Delapril. Am. J. Hypertens. 4(1 Pt 2), 42S-45S (1991).
32. Ogihara T. Practitioner's Trial on the Efficacy of Antihypertensive Treatment in the Elderly Hypertension (The PATE-Hypertension Study) in Japan. Am. J. Hypertens. 13, 461-467 (2000).
33. Omboni S, Fogari R, Mancia G. A smooth blood pressure control is obtained over 24 h by delapril in mild to moderate essential hypertensives. Blood Press. 10, 170-175 (2001).
34. Shiba T, Inoue M, Tada H et al. Delapril versus manidipine in hypertensive therapy to halt type-2-diabetes-mellitus-associated nephropathy. Diabetes Res. Clin. Pract. 47, 97-104 (2000).
35. Zoppi A, Mugellini A, Preti P et al. Effects of the fixed combination of manidipine plus delapril in the treatment of hypertension inadequately controlled by monotherapy with either component: a Phase III, multicenter, open-label, clinical trial. Curr Ther. Res. Clin. Exp. 64, 422-433 (2003).
36. Mugellini A, Vaccarella A, Celentano A et al. Fixed combination of manidipine and delapril in the treatment of mild to moderate essential hypertension: Evaluation by 24-hour ambulatory blood pressure monitoring. Blood Press. 14(Suppl. 1), 6-13 (2005).
37. Mugellini A, Dobovisek J, Planinc D et al. Efficacy and safety of delapril plus manidipine compared with enalapril plus hydrochlorothiazide in mild to moderate essential hypertension: results of a randomized trial. Clin. Ther. 26, 1419-1426 (2004).
38. Karpati P, Alberici M, Tocci G et al. Long-term tolerability and efficacy of the fixed combination of manidipine and delapril in patients with essential hypertension. High. Blood. Press. Cardiovasc. Prev. 10, 81-86 (2003).
39. Preti P, Destro M, Lazzari P et al. Efficacy and tolerability of delapril-manidipine combination vs olmesartan-hydrochlorothiazide fixed combinations in elderly diabetic hypertensive patients. American Society of Hypertension 21st Annual Meeting. NY, USA 16-20 May 2006 (Abstract P 219).
40. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N. Engl. J. Med. 329, 1456-1462 (1993).
41. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to Type 2 diabetes. N. Engl. J. Med. 345, 851-860 (2001).
42. Pohl MA, Blumenthal S, Cordonnier DJ et al. Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the Irbesartan Diabetic Nephropathy Trial. J. Am. Soc. Nephrol. 16, 3027-37 (2005).
43. Wenzel RR. Renal protection in hypertensive patients: selection of antihypertensive therapy. Drugs 65(Suppl. 2), 29-39 (2005).
44. Bellinghieri G, Mazzaglia, Savica V, Santoro, D. Effects of manidipine and nifedipine on blood pressure and renal function in patients with chronic renal failure: a multicenter randomized controlled trial. Ren. Fail. 25, 681-689 (2003).
45. Del Vecchio L, Pozzi M, Salvetti A et al. Efficacy and tolerability of manidipine in the treatment of hypertension in patients with non-diabetic chronic kidney disease without glomerular disease. Prospective, randomized, double-blind study of parallel groups in comparison with enalapril. J. Nephrol. 17, 261-269 (2004).
46. Deerochanawong C, Kornthong P, Phongwiratchai S, Serirat S. Effects on urinary albumin excretion and renal function changes by delapril and manidipine in normotensive Type 2 diabetic patients with microalbuminuria. J. Med. Assoc. Thai. 84, 234-241 (2001).
47. Fogari R, Mugellini A, Zoppi A. et al. Effect of successful hypertension control by manidipine or lisinopril on albuminuria and left ventricular mass in diabetic hypertensive patients with microalbuminuria. Eur. J. Clin. Pharmacol. 61, 483-490 (2005).
48. Kjeldsen S, Julius, S. Hypertension megatrials with cardiovascular end points: effect of angiotensin-converting enzymes inhibitors and angiotensin receptor blockers. Am. Heart J. 148, 747-754 (2004).
49. Schmieder R, Schlaich M, Klingbeil A et al. Update on reversal of left ventricular hypertrophy in essential hypertension (a meta-analysis of all randomized double-blind studies until December 1996). Nephrol. Dial. Transplant. 13, 564-569 (1998).
50. Folsom AR, Rosamond WD, Shahar E et al. Prospective study of markers of hemostatic function with risk of ischemic stroke. The Atherosclerosis Risk in Communities (ARIC) Study Investigators. Circulation 100, 736-742 (1999).
51. Held C, Hjemdahl P, Hakan Wallen N et al. Inflammatory and hemostatic markers in relation to cardiovascular prognosis in patients with stable angina pectoris. Results from the APSIS study. The Angina Prognosis Study in Stockholm. Atherosclerosis 148, 179-188 (2000).
52. Fogari R, Malamani GD, Savino S et al. Effects of different dihydropyridine calcium antagonists on pretibial subcutaneous tissue pressure in hypertensive patients. Am. J. Hypertens. 11(4 Pt 2), 114A (1998).
53. Zanchetti A, Omboni S, La Commare P et al. Efficacy, tolerability, and impact on quality of life of long-term treatment with manidipine or amlodipine in patients with essential hypertension. J. Cardiovasc. Pharmacol. 38, 642-650 (2001).
54. Chiesi Farmaceutici S.p.A. Summary of product characteristics (Delaket 15 mg and 30 mg tablets) (2005).
55. Ogihara T, Mikami H, Katahira K, Otsuka A. Comparative study of the effects of three angiotensin converting enzyme inhibitors on the cough reflex. Am. J. Hypertens. 4(1 Pt 2), 46S-51S (1991).
56. Fogari R, Malamani GD, Derosa G et al. Effect of delapril addition to manidipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients. Am. J. Hypertens. 16(5 Pt 2), 113A (2003).
57. Fogari R, Malamani GD, Zoppi A et al. Effect of benazepril addition to amlodipine on the ankle oedema and subcutaneous tissue pressure in hypertensive patients. J. Hum. Hypertens. 17, 207-212 (2003).
58. Trimarco B, Arcucci O, Gaciong Z et al. Evaluation of different combination of antihypertensive drugs in hypertensive patients not adequately controlled by previous monotherapy. High. Blood. Press. Cardiovasc. Prev. 12(3), 180 (2005).
59. Fang J, Alderman MH. Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey. JAMA 283, 2404-2410 (2000).
60. Prisant LM, Weir MR, Papademetriou V et al. Low-dose combination therapy: an alternative first-line approach to hypertension treatment. Am. Heart J. 130, 359-366 (1995).
61. Messerli FH. Combinations in the treatment of hypertension: ACE inhibitors and calcium antagonists. Am. J. Hypertens. 12(8 Pt 2), 86S-90S (1999).
62. Ram C. Getting to goal in complex patients. Clin. Cardiol. 26(Suppl II, 3-6 (2003).